[4] Conditions that match a drugs FDA approval generally qualify, whether youre using these major GLP-1 brands or similar: Ozempic/Mounjaro: type 2 diabetes [5] Wegovy/Zepbound: obesity (BMI 30) [6] Wegovy/Zepbound: overweight with at least one weight-related condition (BMI 27 to under 30 plus hypertension, high cholesterol, sleep apnea, cardiovascular disease, or type 2 diabetes) [7] Zepbound: obstructive sleep apnea [8] Wegovy: metabolic-associated steatohepatitis (MASH) [9] Off-label conditions can count too when your clinician documents a real diagnosis such as prediabetes, binge eating disorder, or PCOS
Helped a bit Good energy
Gastrointestinal malabsorption: Patients with Crohns disease, celiac disease, gastric bypass or intestinal surgery often cant absorb B12 properly
A safety review in the Journal of Obesity & Food Metabolism describes six randomized, double-blind, placebo-controlled trials evaluating AOD-9604, including oral dosing studies and longer phase II programs
Scott Galloway has called the food industry an obesity index and predicted a tsunami of shareholder destruction. The Cornell data suggests hes directionally right but possibly too aggressive on timing
